Trial Information

Summary: A Phase 3, Randomized, Open-label Study Evaluating DN-101 in Combination with Docetaxel in Androgen Independent Prostate Cancer (AIPC) (ASCENT2)

ASCENT-2 Clinical Trial
For men with advanced prostate cancer
Now enrolling!

Ascent-2 is a study for men with metastatic prostate cancer and for whom treatment with hormone therapy has stopped working. This Phase 3 trial is testing an investigational drug called DN-101 in combination with the chemotherapy drug Taxotere and comparing it to the currently approved regimen of Taxotere plus prednisone.

Enrollment is now taking place at study sites in the US and Canada.

For more information,

Contact:

Staten Island Urological Research, P.C.
1800 Clove Road
Staten Island, NY 10304
Telephone: 718-720-6040
Fax: 718-720-6523
Email:

Profile Page: Staten Island Urological Research, P.C., Staten Island, NY

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:30:08 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA